The study, undertaken at the British Columbia Cancer Agency, Vancouver, found that women with early stage breast cancer treated with up to 4 courses of standard adjuvant anthracycline showed no relationship between dose intensity and clinical outcome, despite nearly a decade of follow-up.
Between 1990 and 1995, 484 patients were assessed in 4 groups: 1- all cycles delivered at full dose and on time; 2- one single dose reduction or dose delay; 3- >1 dose reduction or dose delay; and 4- With an average follow-up of 9.6 years, the researchers found no significant differences in relapse-free survival, breast cancer-specific survival, or overall survival between the 4 groups.
Reductions in the dose intensity (DI) of adjuvant anthracycline based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. Side effects from the therapy can include nausea, fever, weight fluctuations, low white blood cell count and general fatigue.
Lead author Dr Anna Tinker noted that “while there is a breadth of chemotherapy options (e.g. anthracycline based, anthracycline and taxane based, dose dense) the anthracycline based regimen remains a commonly used form of chemotherapy. It may be considered as the sole treatment modality in low risk, endocrine non-responsive disease, or more often, it will form part of a treatment plan such as AC for 4 cycles followed by a taxane, with or with out subsequent hormone therapy or trastuzumab. Therefore, it is important to understand the possible impact of dose modifications of AC therapy on clinical outcomes”.
Recognising a threshold effect of both cumulative dose and dose intensity of anthracyclines, and in light of emerging evidence that dosing schedules may impact on outcome in women with node positive breast cancer, oncologists are often concerned that any single dose modifications or delays will compromise clinical benefit. Oncologists are known to utilise haematopoietic growth factors if dose reductions or delays in adjuvant anthracycline based chemotherapy have been required. Recent data also suggests that chemotherapy dose intensity may be particularly important for patients with ER(-) disease.
However, this retrospective population-based analysis of women with early stage breast cancer treated with up to 4 courses of standard adjuvant AC has not identified a relationship between DI and clinical outcome. When endocrine responsiveness was considered no difference in outcome was appreciated between the 4 groups.
Linda Cairns | alfa
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy